S'abonner

Target genes regulated by CLEC16A intronic region associated with common variable immunodeficiency - 05/06/24

Doi : 10.1016/j.jaci.2023.12.023 
Xubo Huang, MD, MS a, , Jinxia Huang, MD, MS a, , , Xiumei Li, MS b, , Jingxian Fan, MS b, g, Desheng Zhou, MD, MS a, Hui-Qi Qu, MD, PhD c, Joseph T. Glessner, PhD c, k, l, Dandan Ji, MS b, Qi Jia, PhD d, Zhiyong Ding, PhD e, Nan Wang, PhD e, Wei Wei, MD f, Xing Lyu, MD f, Mulin Jun Li, PhD g, Zhe Liu, PhD h, Wei Liu, MD i, j, Yongjie Wei, PhD a, Hakon Hakonarson, MD, PhD c, k, l, Qianghua Xia, PhD b, g, , Jin Li, PhD b, f,
a Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China 
b Department of Cell Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory of Medical Epigenetics, Tianjin Institute of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China 
g Department of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China 
h Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China 
f Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China 
i Tianjin Children’s Hospital (Tianjin University Children’s Hospital), Tianjin, China 
j Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China 
c Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, Pa 
k Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, Pa 
l Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa 
d International School of Information Science Engineering, Dalian University of Technology, Dalian, China 
e Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd, Jinan, China 

Corresponding author: Jin Li, PhD, Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.Department of Cell Biology2011 Collaborative Innovation Center of Tianjin for Medical EpigeneticsTianjin Medical UniversityTianjin300070ChinaQianghua Xia, PhD, Department of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.Department of BioinformaticsSchool of Basic Medical SciencesTianjin Medical UniversityTianjin300070China

Abstract

Background

CLEC16A intron 19 has been identified as a candidate locus for common variable immunodeficiency (CVID).

Objectives

This study sought to elucidate the molecular mechanism by which variants at the CLEC16A intronic locus may contribute to the pathogenesis of CVID.

Methods

The investigators performed fine-mapping of the CLEC16A locus in a CVID cohort, then deleted the candidate functional SNP in T-cell lines by the CRISPR-Cas9 technique and conducted RNA-sequencing to identify target gene(s). The interactions between the CLEC16A locus and its target genes were identified using circular chromosome conformation capture. The transcription factor complexes mediating the chromatin interactions were determined by proteomic approach. The molecular pathways regulated by the CLEC16A locus were examined by RNA-sequencing and reverse phase protein array.

Results

This study showed that the CLEC16A locus is an enhancer regulating expression of multiple target genes including a distant gene ATF7IP2 through chromatin interactions. Distinct transcription factor complexes mediate the chromatin interactions in an allele-specific manner. Disruption of the CLEC16A locus affects the AKT signaling pathway, as well as the molecular response of CD4+ T cells to immune stimulation.

Conclusions

Through multiomics and targeted experimental approaches, this study elucidated the underlying target genes and signaling pathways involved in the genetic association of CLEC16A with CVID, and highlighted plausible molecular targets for developing novel therapeutics.

Le texte complet de cet article est disponible en PDF.

Key words : AKT, autoimmunity, chromatin interaction, CLEC16A, common variable immunodeficiency disorder, primary immunodeficiency

Abbreviations used : CHOP, CVID, DEG, FC, GWAS, KO, MS, PIDD, PMA, RA, RNA-seq, SILAC


Plan


© 2024  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 153 - N° 6

P. 1668-1680 - juin 2024 Retour au numéro
Article précédent Article précédent
  • Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals
  • Ottavia M. Delmonte, Cihan Oguz, Kerry Dobbs, Katherine Myint-Hpu, Boaz Palterer, Michael S. Abers, Deborah Draper, Meng Truong, Ian M. Kaplan, Rachel M. Gittelman, Yu Zhang, Lindsey B. Rosen, Andrew L. Snow, Clifton L. Dalgard, Peter D. Burbelo, Luisa Imberti, Alessandra Sottini, Eugenia Quiros-Roldan, Francesco Castelli, Camillo Rossi, Duilio Brugnoni, Andrea Biondi, Laura Rachele Bettini, Mariella D’Angio, Paolo Bonfanti, Megan V. Anderson, Annalisa Saracino, Maria Chironna, Mariantonietta Di Stefano, Jose Ramon Fiore, Teresa Santantonio, Riccardo Castagnoli, Gian Luigi Marseglia, Mary Magliocco, Marita Bosticardo, Francesca Pala, Elana Shaw, Helen Matthews, Sarah E. Weber, Sandhya Xirasagar, Jason Barnett, Andrew J. Oler, Dimana Dimitrova, Jenna R.E. Bergerson, David H. McDermott, V. Koneti Rao, Philip M. Murphy, Steven M. Holland, Andrea Lisco, Helen C. Su, Michail S. Lionakis, Jeffrey I. Cohen, Alexandra F. Freeman, Thomas M. Snyder, Justin Lack, Luigi D. Notarangelo
| Article suivant Article suivant
  • Effect of age and season on respiratory mucosal immune marker profiles
  • Esther van Woudenbergh, Debbie M. van Rooijen, Janine J. Veldman-Wolf, Mioara A. Nicolaie, Martijn A. Huynen, Fiona R.M. van der Klis, Marien I. de Jonge, Gerco den Hartog

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.